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OBJECTIVE—b-Cells that express an imaging reporter have pro-
vided powerful tools for studying b-cell development, islet trans-
plantation, and b-cell autoimmunity. To further expedite diabetes
research, we generated transgenic C57BL/6 “MIP-TF” mice that
have a mouse insulin promoter (MIP) driving the expression of
a trifusion (TF) protein of three imaging reporters (luciferase/
enhanced green ﬂuorescent protein/HSV1-sr39 thymidine kinase)
in their b-cells. This should enable the noninvasive imaging of
b-cells by charge-coupled device (CCD) and micro-positron emis-
sion tomography (PET), as well as the identiﬁcation of b-cells at
the cellular level by ﬂuorescent microscopy.
RESEARCH DESIGN AND METHODS—MIP-TF mouse b-cells
were multimodality imaged in models of type 1 and type 2 di-
abetes.
RESULTS—MIP-TF mouse b-cells were readily identiﬁed in pan-
creatic tissue sections using ﬂuorescent microscopy. We show that
MIP-TF b-cells can be noninvasively imaged using microPET.
There was a correlation between CCD and microPET signals from
the pancreas region of individual mice. After low-dose streptozo-
tocin administration to induce type 1 diabetes, we observed a pro-
gressive reduction in bioluminescence from the pancreas region
before the appearance of hyperglycemia. Although there have
been reports of hyperglycemia inducing proinsulin expression
in extrapancreatic tissues, we did not observe bioluminescent
signals from extrapancreatic tissues of diabetic MIP-TF mice.
Because MIP-TF mouse b-cells express a viral thymidine kinase,
ganciclovir treatment induced hyperglycemia, providing a new
experimental model of type 1 diabetes. Mice fed a high-fat diet
to model early type 2 diabetes displayed a progressive increase in
their pancreatic bioluminescent signals, which were positively
correlated with area under the curve–intraperitoneal glucose tol-
erance test (AUC-IPGTT).
CONCLUSIONS—MIP-TF mice provide a new tool for monitor-
ing b-cells from the single cell level to noninvasive assessments
of b-cells in models of type 1 diabetes and type 2 diabetes.
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T
he expression of imaging reporter genes in
b-cells has provided powerful tools for studying
b-cell development, embryonic and adult stem
cell differentiation into b-cells, transdifferenti-
ation, and islet transplantation (1–13). Bioluminescent
reporters, such as ﬁreﬂy luciferase, emit photons that can
be detected with high sensitivity using a cooled charge-
coupled device (CCD). We and others have demonstrated
human and rodent islets can be genetically engineered ex
vivo to express luciferase so that the islets can be moni-
tored following their transplantation by CCD and that CCD
signal corresponded with the implanted b-cell mass (1,2).
Several laboratories have generated transgenic mice that
express luciferase in their b-cells and shown that the CCD
signal from the pancreas is correlated with b-cell mass (3–5).
Moreover, the transgenic islets can be monitored after
transplantation (3,4,6). Fluorescence imaging and biolumi-
nescence imaging (BLI) are highly useful for research
purposes in small animals, but they are not yet applicable
to imaging internal organs in large animals because of the
limited transparency of tissues to photons.
Positron emission tomography (PET) imaging is used
clinically to assess various disorders of the heart and brain
and for detecting various cancers (7,8). Islets that were
engineered ex vivo to express a PET can be noninvasively
monitored by microPET after implantation into the liver
(9,10). The microPET signal reﬂects b-cell mass, and islets
can be monitored long-term after implantation (11). Ra-
diolabeled ligands of vesicular monoamine transporter
(VMAT2) can image b-cells in BB rats, although VMAT2
may not be a sensitive biomarker of b-cell mass in humans
(12–14). Mouse pancreatic b-cells are inherently difﬁcult to
detect by microPET because of the small size of mice, the
long thin shape of the pancreas and its proximity to the
probe excretion pathway—which eliminates the vast ma-
jority of the tracer and obscures the weaker signals from
the pancreas, and the resolution of microPET (1–2m m
3).
Recent advances in PET reporter genes and PET probes
with better clearance kinetics and biodistribution, how-
ever, have allowed progress towards microPET imaging of
mouse b-cells in situ (14).
Previous imaging studies of b-cells have used animal
models in which the b-cells express a single reporter gene.
We have developed a series of trifusion imaging reporters
consisting of a bioluminescent reporter (e.g., luciferase),
linked by a few alanine residues to a ﬂuorescent reporter
gene (e.g., enhanced green ﬂuorescent protein [EGFP]),
which in turn is linked to a PET reporter (e.g., herpes
simplex virus [HSV] thymidine kinase) (15). All three
reporters are expressed as a single fusion protein, allowing
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ORIGINAL ARTICLEnoninvasive CCD and PET imaging, as well as ﬂuorescent
microscopic analysis of tissue sections or ﬂuorescence-
activated cell sorter (FACS) isolation of single cells ex-
pressing EGFP (15,16). Using an insulin promoter to drive
the expression of a trifusion reporter in transgenic mouse
b-cells should enable the longitudinal monitoring of b-cells
in the same mice by both CCD and microPET. After killing,
ﬂuorescent microscopy can identify b-cells at the cellular
level and facilitate correlation of b-cell number and mass
with the CCD and microPET signals. Because all three
reporters are linked together in a fusion protein, the mag-
nitude of signals from one imaging reporter should pre-
dict the magnitude of the signals from the other imaging
reporters. Here, we provide proof-of principle of the utility
of mice expressing a trifusion imaging reporter speciﬁcally
in their b-cells in mouse models of type 1 diabetes and type
2 diabetes.
RESEARCH DESIGN AND METHODS
Animals. C57BL/6 MIP-TF mice were generated by injecting fertilized C57BL/6
oocytes with the MIP-TF DNA fragment described below. Founder mice were
bred with C57BL/6 mice. We noticed some decline in the levels of pancreatic
CCD signals with successive generations of MIP-TF mice. Therefore, we
screened potential MIP-TF breeders or a few of their offspring for their pan-
creatic bioluminescent signal by CCD and used those with high pancreatic
luciferase expression for breeding. This stabilized the pancreatic expression of
luciferase at high levels in subsequent generations. Mice from line 300 were
donated to the type 1 diabetes resource at The Jackson Laboratory (stock no.
12943 C57BL/6-Tg[Ins2-luc/EGFP/Tk]300Kauf/J). The MIP-TF transgene is also
being bred into the NOD mouse background (stock no. 13116). FVB Tg(RIP-luc)
micewereobtainedfromXenogen(nowCaliperLifeSciences,Alameda,CA)(3).
MIP-GFP mice were generously provided by Manami Hara (17). All transgenic
mice studied were heterozygotic for the transgene. All experimental protocols
were approved by the University of California, Los Angeles Animal Research
Committee.
Generation of MIP-TF transgenic mice. We previously constructed a series
of different cDNAs encoding fusions of three imaging reporter proteins with
different properties for bioluminescent, ﬂuorescent, and PET imaging (15). We
chose a trifusion cDNA construct containing the following: 1) a mutant ﬁreﬂy
luciferase gene, which was modiﬁed for higher enzymatic activity at 37°C and
therefore enhanced bioluminescent imaging in vivo; 2) EGFP because of its
stronger ﬂuorescent signal relative to GFP; and 3) HSV1-sr39TK, which is
modiﬁed for nuclear translocation and enhanced activity for PET probes (15).
The trifusion cDNA was ampliﬁed using forward primer 59-GCGCaacgttATG
GAAGACGCCAAAAACAT-39 containing an AclI site (restriction sites indicated
by lower case) and reverse primer 59-ACGCgtcgacCCGCATCCCCAGCATG
CCTGC-39 (containing a SalI site), which is downstream of the trifusion cDNA
stop codon and polyadenylation sequence. A 3.5-kb fragment containing the
promoter region of the mouse insulin II gene (beginning 3.5 kb upstream of the
ATG translational start signal and ending at this ATG) was ampliﬁed from
129/Sv mouse genomic DNA by PCR using forward primer 59-CTGCatgcatAGG
CTCCCATTCAGTCATTG-39 (containing a NsiI site) and reverse primer 59-
GTCCatcgatggcgccggcCATGTTGAAACAATAACC-39 (containing ClaI, NarI,
NaeI sites). A region starting in insulin exon 2 and extending 3.6 kb 39
downstream was PCR ampliﬁed using forward primer 59-GCCGctcgagA
AGCAGCACCTTTGTGGTTC-39 (containing a XhoI site) and reverse primer 59-
GATCgacgtcTGACCTCTGCTGGACGCTTC-39 (containing an AatII site). These
PCR fragments were cloned sequentially into pNeoﬂox8 (removing the ﬂox
and Neomycin sequences) to generate pLARA-MIP-TF (Fig. 1A). In this con-
struct, the trifusion cDNA (containing a stop and polyadenylation signal) is
placed just downstream of the translational start signal of preproinsulin and
then linked to 3.6 kb of downstream mouse insulin II genomic DNA, beginning
within exon 2 to preserve any 39 intron sequences that could contain tran-
scription regulatory sequences. After ampliﬁcation in transformed Escher-
ichia coli the entire insert was excised, puriﬁed, and microinjected into
C57BL/6 fertilized oocytes, which were then implanted into pseudopregnant
C57BL/6 surrogate mothers. The resulting offspring were screened for the
transgene by testing tail DNA for the presence of the EGFP gene (forward
primer: 59-AAATCGCTCCGGATACTGCG-39 and reverse primer: 5-AGGGTTG
GTACTAGCAACGC-39). The transgenic lines were expanded by mating with
wild-type C57BL/6 mice.
Diets. Mice were housed in microisolator caging and provided normal chow
(LaboratoryResearchDiets,Catalog5001).Whereindicated,malemice(8weeks
old) were fed high-fat diet (HFD) containing 60% fat (Research Diets, D12492).
Food and water were available ad libitum at all times except for a 14- to 16-h
fasting period before intraperitoneal glucose tolerance test (IPGTT).
Bioluminescence imaging. Anesthetized mice were injected intraperitoneally
with 126 mg/kg D-Luciferin (15 mg/mL in PBS). The mice were scanned using
a CCD device (Caliper-IVIS; Caliper Life Sciences, Hopkinton, MA), as pre-
viously described (1). The ﬁreﬂy luciferase in the trifusion reporter has an
emission of light centered on 560 nm, and the CCD camera has maximal
quantum efﬁciency at 550–650 nm. Twelve consecutive bioluminescence
images were obtained and analyzed using LIVING IMAGE 4 software (Caliper
Life Sciences) with an acquisition time of 1 min for each frame. A photo-
graphic grayscale scale reference image was obtained under low-level illu-
mination. To quantify emitted light, regions of interest were drawn over the
pancreas region, and maximum photons/seconds/squared centimeters/steradian
was determined. The data shown are the average of four maximum regions of
interest values over the scanning period. Linear line graphs were plotted using
Microsoft Excel 2003 software.
For bioluminescence imaging of isolated organs, mice were killed under
anesthesia. Their pancreas, spleen, liver, kidney, lung, heart, brain, spinal cord,
muscle,andskintissueswerequicklydissectedoutandplacedinseparatewells
of a 16-well plate containing D-Luciferin (4.3 mg/mL) in PBS at 37°C. Bio-
luminescence images were taken with an acquisition time of 1 min and max-
imum bioluminescence in photons/seconds/squared centimeters/steradian was
determined.
Luminescent bead imaging. A constant intensity luminescent bead (Mb-
Microtec, Bern, Switzerland) was used to measure attenuation of pancreatic
luminescence by overlaying tissue, as previously described (2,18). Three days
after the ﬁnal CCD scan, MIP-TF mice were killed and a small incision was
immediately made on their ventral left side and a luminescent bead was inserted
underneath the fat and above the pancreas head. The animal was imaged using
an IVIS Lumina II imaging system (Caliper Life Sciences) with 1-s exposure.
Attenuation was quantiﬁed by comparing the luminescence of the implanted
bead versus the luminescence ex vivo of the bead. The slope of the linear re-
gression relating the luminescence of the bead to mouse weight was used to
normalize BLI measurements for mice fed a HFD.
Luciferase enzymatic activity assay. Luciferase activity was determined
using a Luciferase Assay Kit (Stratagene). Brieﬂy, pancreata of MIP-TF mice
and control C57BL/6 mice were divided along their length (head to tail). One
half was sonicated in 1 mL cell lysis buffer (Stratagene) for the luciferase
activityassay,andtheotherhalfwasimmediatelyﬁxedin4%paraformaldehyde
(PFA) for histology. The homogenates were centrifuged at 15,000g for 15 min
in a microcentrifuge. Protein concentrations in supernatants were determined
using a Dc protein assay kit (Bio-Rad) and adjusted to 1 mg/mL. Luciferase
activity was assayed in triplicate using 50 mL tissue homogenate with 100 mL
assay buffer mixture in an opaque-walled 96-well plate (Corning) by a
luminometer (Analyst HT).
Glucose tolerance test. To assess glucose tolerance, mice were fastedfor 16h
and weighed.Themicewerechallengedwithaglucosesolution(2mg/gi.p.),and
their blood glucose levels were determined using a One Touch Ultra blood
glucose monitor (Johnson and Johnson) 0, 15, 30, 60, 90, 120, and 150 min
postinjection. Area under the curve (AUC) was calculated by the trapezoid rule
for the glucose tolerance curve using Origin 6.0 software (Microsoft).
Streptozotocin, alloxan, and ganciclovir administration. A high dose of
streptozotocin(STZ)(200mg/kg)or a low dose of STZ (40 mg/kg i.p. ﬁve times)
w a su s e dt oa b l a t eb-cells as indicated. Other mice were rendered diabetic by
a low dose of alloxan (two administrations of 80 mg/kg i.v., 3 days apart) or
administration of a low dose of ganciclovir (GCV; 50–75 mg/kg CYTOVENE-IV
sodium salt [Roche Laboratories, Nutley, NJ]) through a subcutaneous mini-
pump (Alzet) for 14 days. Diabetes onset was considered to be two consecutive
blood glucose readings of .300 mg/dL.
Immunohistochemistry and pancreatic b-cell area determination. After
ﬁxation in 4% PFA overnight, pancreata were cryoprotected in 30% sucrose (in
PBS) at 4°C until tissue sank to the bottom. Pancreata were then embedded in
optimal cutting temperature compound and were sectioned into 5-mm thick
slices. Slides were air-dried at room temperature for 30 min and stored
at 220°C until use. Fixed pancreas sections were incubated with polyclonal
anti-insulin from guinea pig (1:500; Cat. 18-0067; Zymed Laboratories), anti-
somatostatin (1:500), or antiglucagon (1:500; Dako) followed by incubation
with AF568 goat anti-guinea pig (insulin) or AF555 goat anti-rabbit (glucagon
and somatostatin) secondary antibodies (Vector Laboratories). Negative
controls included incubation with normal guinea pig or rabbit serum. Immu-
noﬂuorescence was examined by an Olympus BX-60 microscope, and micro-
scopic images were taken with a Macroﬁre camera mounted atop the microscope
(Optronics; N = at least three mice/group). For ﬂuorescence microscopy, the
following wavelengths were used: Alexa-568; excitation-578 nm/emission-603 nm;
EGFP excitation-489 nm/emission-508 nm; DAPI, excitation wavelength-360 nm/
emission wavelength-460 nm.
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rated by 50 mm) were stained with anti-insulin (by the 3,39 diaminobenzidine
color reaction), scanned using an Aperio ScanScope system, and then exam-
ined using Aperio ImageScope software. b-Cell area was deﬁned as: insulin-
positive area 3 100/total pancreas tissue area (%). The average b-cell area
(calculated by averaging three sections spaced by 100 mm at three different
levels of the pancreas) for individual mice is shown, with four to six mice in
each group.
MicroPET imaging, micro-computed tomography scanning, and microPET
data analysis. These methods are detailed in Supplementary Data.
FIG. 1. Generation and characterization of MIP-TF mice. A: Diagrammatic representation of the construct used for microinjection. The trifusion
reporter cDNA (ﬁreﬂy luciferase/EGFP/truncated HSV1-sr39TK) (15) is ﬂanked on its 59 end by 3.5 kb of genomic DNA upstream of the mouse
insulin II ATG translational start site and, on its 39 end, has 3.6 kb of genomic DNA that lies immediately 39 of the ATG translational start site of
insulin II. Exons of the insulin II gene are indicated as E1–3. B: Bioluminescence was detected speciﬁcally from the pancreas region of line 300
mice (referred to as MIP-TF mice; at left), but not a nontransgenic littermate (at right). The sides of both mice were shaved to maximize detection
of bioluminescence. C: Representative BLI of freshly dissected organs from a MIP-TF mouse after luciferase injection. Top row (left to right):
pancreas, liver, spleen, and heart; bottom row (left to right): lung, thymus, muscle, and brain. D: In vivo bioluminescence (measured as maximal
radiance) showed a linear correlation with luciferase activity in pancreas homogenates (R
2 = 0.66, P < 0.05). E: IPGTT test. Data shown are the
mean blood glucose levels after glucose challenge 6 SEM; n = 14 mice/group. F–H: Expression of EGFP in b-cells of MIP-TF mice. Pancreas sections
from MIP-TF mice were immunostained for insulin (red) and examined for EGFP expression (green) by ﬂuorescence microscopy. Only insulin-
positive cells also expressed EGFP. There was no overlap of EGFP expression (green) with glucagon (red; I), or somatostatin (J). Islets from mice
rendered diabetic with STZ had few or no EGFP-expressing islet cells (K). (A high-quality color representation of this ﬁgure is available in the
online issue.)
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Generation and characterization of transgenic mice
expressing a TF reporter gene. A genomic fragment,
which extended 3.5 kb 59 from the ATG translational start
site (containing the promoter, exon 1, intron 1, and part of
exon 2), of the mouse insulin II gene was subcloned 59 of
a TF cDNA containing a translational stop and poly-
adenylation signals on its 39 end (Fig. 1A). To the 39 end of
the TF cDNA we linked the rest of the insulin II gene, be-
ginning just after the ATG start site of insulin and extending
3.6 kb downstream (including the rest of exon 2, intron 2,
exon 3, and additional noncoding region). The insulin II
gene promoter was chosen because this gene is the pre-
dominant source for insulin synthesis in murine pancreatic
b-cells (19). We injected the MIP-TF DNA cassette into
fertilized C57BL/6 oocytes. Four founder transgenic mice
were obtained (numbered 300, 324, 341, and 348), and each
mouse line was expanded by mating with wild-type C57BL/6
mice. Their offspring were screened for the presence of TF
gene by PCR. Transgene negative littermates were used as
age-matched wild-type C57BL/6 controls.
Mice of line 324 had a strong bioluminescence signal
from their pancreatic region, head, and spine (data not
shown). Luciferase expression in the brain and spinal cord
was veriﬁed by injecting the mice with D-Luciferin, dis-
secting out their major organs, and imaging the organs
ex vivo with CCD. Histological analysis of their brains
showed that luciferase expression occurred particularly
in the choroid plexus. A previous study of mice with a
b-galactosidase cDNA knocked into an insulin II gene ob-
served expression of b-galactosidase in the b-cells and the
choroid plexus of the brain (20). These observations, as
well as others (19), support the notion that proinsulin may
be expressed in the central nervous system. Mice from line
341 displayed weak bioluminescence signals from their
pancreas region and from the ventral side of their necks
(data not shown). The latter may reﬂect expression of
proinsulin in the thymus, as described previously (19,21).
Mice from lines 300 and 348 had bioluminescence signals
exclusively from their pancreas region (mouse line 300
shown in Fig. 1B). The pancreatic BLI signals were higher
from mouse line 300 than from line 348, so mouse line 300
was used for all subsequent studies. These mice are re-
ferred to hereafter as C57BL/6 MIP-TF mice. To verify the
source of the bioluminescence, we injected MIP-TF mice
with D-Luciferin, dissected out their pancreata, spleen,
liver, kidney, lung, heart, brain, spinal cord, and muscle,
and scanned them by CCD. As expected, only the pan-
creata emitted a bioluminescent signal (Fig. 1C), conﬁrm-
ing that the reporter gene was exclusively expressed in the
pancreas. After CCD imaging, pancreata from individual
C57BL/6 MIP-TF mice were homogenized and assayed for
luciferase enzymatic activity in vitro. The luciferase en-
zymatic activity showed a linear correlation with the
magnitude of the pancreatic bioluminescent signal from
individual animals (P , 0.05; Fig. 1D). There were no
detectable bioluminescent signals or luciferase activity
from wild-type mice or their dissected organs (data not
shown). Importantly, age-matched MIP-TF and wild-type
mice had similar responses to intraperitoneal glucose
challenge (Fig. 1E), indicating that the transgene did not
interfere with the b-cell response to a glucose challenge.
To examine the expression of the trifusion reporter at
the cellular level, pancreas sections from MIP-TF mice
were immunostained for insulin and examined for EGFP
expression. Fluorescent microscopic analysis of pancreas
tissue sections showed that EGFP expression was limited
to cells that also expressed insulin (Fig. 1F–H). There was
some variability in the EGFP intensity of ﬂuorescence among
islet b-cells, as has also been observed in other transgenic
mice expressing imaging reporters in b-cells (3,6,22) and our
own observations in pancreata from MIP-EGFP mice (17).
There was no overlap of EGFP expression with glucagon
(Fig. 1I) or somatostatin (Fig. 1J) expression. Islets from
mice rendered diabetic by STZ administration had few, or
no, cells that expressed EGFP (Fig. 1K). Thus the trans-
gene is speciﬁcally expressed in MIP-TF mouse b-cells.
Evaluation of Tg(RIP-luc) mice. Concurrent with our
studies of MIP-TF mice, we also characterized transgenic
FVB/N mice that express luciferase (only) under the con-
trol of a rat insulin II promoter (Tg[RIP-luc mice]) (3,23),
obtained from Xenogen (now Caliper Life Sciences). We
found that the bioluminescent signals from their pancreas
were about 20-fold less than that from MIP-TF mouse
pancreas (Fig. 1B vs. Fig. 2). After Tg(RIP-luc) mice were
given a high dose of STZ, the bioluminescent signal from
their pancreas region rapidly declined, but a strong signal
from their liver region arose a few days after STZ admin-
istration (Fig. 2), matching recent observations in these
mice, which localized the transgene expression to occa-
sional oval cells in their liver (23). We conﬁrmed that the
bioluminescence originated from the liver of diabetic Tg
(RIP-luc) mice by CCD imaging isolated livers ex vivo
(data not shown). Chan and colleagues (24) observed that
hyperglycemia induces proinsulin expression in liver cells.
However, we observed that some Tg(RIP-luc) mice given
low doses of STZ or alloxan, which did not develop hy-
perglycemia, still had a rapid induction of a bioluminescent
signal from their liver, although this signal was weaker
than that following high-dose STZ administration. In con-
trast, neither high- nor low-dose STZ administration in-
duced detectable transgene expression in MIP-EGFP (17)
mouse livers (as measured by in vitro assay of liver ho-
mogenate ﬂuorescence, data not shown) or in the liver of
our MIP-TF mice (as measured by in vitro assays of ﬂuo-
rescence and luciferase activity in liver homogenates, data
not shown) and by BLI of living MIP-TF mice as described
below. The expression of luciferase in the liver of normo-
glycemic low-dose STZ and alloxan-induced Tg(RIP-luc)
1
0
3
 
p
/
s
/
c
m
2
/
s
r
400
300
200
100
+
FIG. 2. STZ-induced expression of luciferase in the liver of Tg(RIP-luc)
mice. Representative image of a Tg(RIP-luc) mouse before (at left) and
10 days after (at right) treatment with a high dose of STZ. The signal
from the nose region of the mouse in the right panel is a reﬂection.
(A high-quality color representation of this ﬁgure is available in the
online issue.)
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the short rat insulin promoter (780 bp) used to drive lu-
ciferase expression, a response to transiently elevated
glucose levels and/or toxin-induced oval cell stress. Nota-
bly, hepatotoxicity is known to activate oval cells, in-
dependent of hyperglycemia (25). We did not study the
Tg(RIP-luc) mice further.
MicroPET imaging of MIP-TF mouse b-cells. The TF
gene contains a modiﬁed thymidine kinase (HSV1-sr39TK)
reporter gene optimized for microPET imaging (15).
[
18F]FHBG has been widely used to image TK-expressing
genes in tumor cells in mouse models. The MIP-TF mice
were ﬁrst imaged by BLI and then microPET scanned using
[
18F]FHBG as a probe (Fig. 3). Six hours after probe injection,
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FIG. 3. MicroPET and CCD imaging of b-cells in MIP-TF mice. Representative CCD and microPET/CT images of a MIP-TF mouse before (A–E and
K) and after (F–J and L) being rendered diabetic with STZ are shown. A and F show CCD images before, and after, STZ treatment, respectively.
The same mouse was injected with [
18F]FHBG and imaged 6 h later with microPET/CT. Two hours before microPET, Fenestra was injected to
provide spleen and liver contrast, so we could identify those organs in the CT images. B–D: Coronal CT scan (B), coronal microPET scan (C), and
merged microPET/CT (D) before STZ treatment. G–I: Coronal CT scan (G), coronal microPET scan (H), and merged microPET/CT (I) after the
mouse was rendered diabetic with STZ. E and J: Sagital microPET/CT images before and after STZ (respectively). K and L: Transverse microPET/
CT images before and after STZ. “L” points to liver, “S” points to spleen, and “P” points to pancreas. Three mice were imaged before and after
being rendered diabetic by STZ administration, and the change in [
18F]FHBG retention in the pancreas region of individual mice is shown (M). All
microPET/CT images are on the same scale. In other experiments, the uptake of [
18F]FHBG in the pancreas region as measured by microPET
imaging 5 h after probe injection was plotted against bioluminescence signal as measured by BLI for individual animals (N). A signiﬁcant linear
correlation (R
2 = 0.41) was found for [
18F]FHBG uptake and bioluminescence (P < 0.05). (A high-quality color representation of this ﬁgure is
available in the online issue.)
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discernable from other organs. Quantitative analysis of pan-
creatic [
18F]FHBG retention revealed that retained [
18F]FHBG
radioactivity was signiﬁcantly correlated with the magni-
tude of the bioluminescence signal from the same animal
(Fig. 3N). After microPET imaging, some mice were ren-
dered diabetic with STZ and then reimaged. Both CCD and
microPET/computed tomography (CT) imaging showed that
there was a great reduction in bioluminescence (Fig. 3F)
and [
18F]FHBG retention (3G-M) from the pancreas region,
conﬁrming that these signals originate from b-cells. Thus
MIP-TF mouse pancreatic b-cells can be detected by
microPET, and there is an association between microPET
and BLI signals, as has been observed in previous in vitro
and in vivo studies using the trifusion reporter system in
tumor models (15,16,26).
Using the low-dose STZ model of type 1 diabetes,
pancreatic bioluminescence declines before the ap-
pearance of hyperglycemia. In an initial study, MIP-TF
mice were given a high dose of STZ (200 mg/kg) or diluent.
Pancreatic bioluminescence was measured by BLI before,
as well as 3, 9, and 16 days after STZ injection. All STZ-
induced diabetic mice (but not control diluent-treated mice)
became highly hyperglycemic 3 days posttreatment, and
their pancreatic bioluminescence dropped to baseline levels
and remained so throughout the observation period (Fig. 4A).
These data provide further evidence that 1) the expression of
the trifusion reporter gene is b-cell speciﬁca n d2) b-cell loss
in MIP-TF mice can be noninvasively monitored by BLI.
Next, we gave MIP-TF mice multiple low doses of STZ
(40 mg/kg) for 5 consecutive days (as per [27]) and mon-
itored their pancreatic bioluminescence longitudinally for
21 days. In this less rapidly progressing model of type 1
diabetes, we clearly detected loss of pancreas region bio-
luminescence before the appearance of hyperglycemia
(Fig. 4B). The bioluminescent signals from the pancreas
were reduced 2 and 4 days after STZ administration to an
average of 63 and 54%, respectively, of the pretreatment
level, during which time the animals remained normogly-
cemic. It was not until 10 days after beginning STZ ad-
ministration that hyperglycemia became apparent, at which
time the pancreatic bioluminescent signals had dropped to
an average of 46% of its initial level. By the time the ani-
mals developed severe hyperglycemia, their pancreatic
bioluminescent levels were on average only 8% of their
initial levels. In contrast, a control group of MIP-TF mice
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FIG. 4. CCD imaging of MIP-TF mice in type 1 diabetes models. A: Longitudinal monitoring of pancreas region bioluminescence and blood glucose
levels in MIP-TF mice given a high dose of STZ administration (200 mg/kg i.p., once) or diluent. Data shown as bars are the mean maximum
photons/seconds/squared centimeters/steradian 6 SEM for MIP-TF mice given STZ (black bars) or diluent (white bars). Solid line indicates mean
blood glucose level 6 SEM for MIP-TF mice given STZ; dashed line is that for diluent-treated mice. After STZ administration, bioluminescence
dropped >300-fold to baseline levels (n = 6 mice/group). B: Longitudinal monitoring of pancreas region bioluminescence and blood glucose levels
in MIP-TF mice that developed hyperglycemia following multiple low doses of STZ (40 mg/kg i.p. for 5 consecutive days). Solid line indicates mean
maximum photons/seconds/squared centimeters/steradian 6 SEM; dashed line represents mean blood glucose levels 6 SEM (n = 3 mice). C: Linear
correlation between b-cell area and BLI for individual diluent or STZ-induced MIP-TF mice (P < 0.05). D: Correlation of pancreatic BLI with b-cell
is from individual mice. D: Pancreatic region bioluminescence before and 14 days after control diluent (white bars) or GCV (black bars) treatment
and the development of hyperglycemia in the latter. Data shown are change in mean bioluminescence (n = 3 mice/group). **P < 0.01.
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pancreatic bioluminescence and blood glucose (data not
shown). After a last CCD scan, the mice were killed and we
determined the islet b-cell area for individual STZ-induced
and diluent-treated MIP-TF mice. We found a linear corre-
lation between b-cell area and bioluminescent signal (Fig.
4C, P , 0.05).
Herpes simplex virus thymidine kinase with ganciclovir
(GCV) is a widely used suicide gene/prodrug system. Be-
cause MIP-TF mice speciﬁcally express HSV1-sr39 thymi-
dine kinase in their b-cells, treatment with GCV should
ablate their b-cells, providing a new experimental model
of type 1 diabetes. MIP-TF mice given a low dose of GCV
developed hyperglycemia within 14 days of treatment at
which time there was an average 72% reduction in the BLI
signal from the pancreas region (Fig. 4D).
CCD monitoring HFD-induced changes in b-cell
function. C 5 7 B L / 6m i c ef e daH F Da r eaw i d e l yu s e d
model of the early stages of type 2 diabetes (28–30).
HFD-fed mice develop glucose intolerance, increase their
b-cell mass, and progress to hyperglycemia. We examined
whether monitoring luciferase expression in MIP-TF mice
by BLI provides a surrogate marker of the increased insulin
gene transcription during the early stages of type 2 diabetes
development.
Eight-week-old MIP-TF mice were placed on a HFD or
normal mouse chow, and their pancreatic bioluminescence
and weight were monitored longitudinally over 60 days.
Both normal chow and HFD-fed mice gained weight over
this observation period, but mice fed the HFD diet gained
weight at a faster rate (Fig. 5A). As expected, HFD feeding
led to elevated fasting blood glucose (data not shown) and
impaired glucose tolerance, as evidenced by signiﬁcantly
increased AUC-IPGTT at day 40 and day 60 compared with
the control diet group (Fig. 5B). On days 10 and 20, the
bioluminescent signals from mice fed a HFD were almost
twofold higher than that of their littermates that were fed
a normal diet (days 10 and 20; Fig. 5A). However, BLI
measurements taken at later time points (days 40 and 60)
showed that pancreatic bioluminescent signals from HFD
and normal chow-fed mice were similar in magnitude. We
surmised that with the progressive development of obe-
sity, the increasing tissue overlying the pancreas blocked
pancreatic bioluminescence to a greater extent in HFD-fed
mice, as was previously observed in a study of HFD-fed
transgenic mice that express luciferase in their b-cells (5).
To discern the extent to which the pancreatic photonic
signal was attenuated by the increased body mass of HFD-
fed animals, the mice were killed a few days after the last
CCD scan, and a ﬂuorescent bead that emits constant
amount of light was implanted above their pancreas and
the mice were CCD imaged, as previously described (5,18).
We found that light from the luminescent bead attenuated
linearly with increasing mouse weight (Fig. 5C, P , 0.01).
The average attenuation of light from the implanted bead
in HFD-fed mice was approximately threefold more than
that in control mice. After correction for this interference,
the pancreatic bioluminescence for HFD-fed group at day
60 was actually 3.6-fold higher than that of control mice
(Fig. 5D, P , 0.05 by two-tailed t test). Moreover, although
uncorrected pancreatic bioluminescence did not correlate
with AUC-IPGTT values at day 60, after correction for at-
tenuation, bioluminescent signals were linearly correlated
with AUC-IPGTT (Fig. 5E, P , 0.01). Finally, we excised
the pancreas and determined pancreatic b-cell area in
individual mice. There was a linear correlation between
b-cell area and the magnitude of the last pancreatic bio-
luminescent signal from individual control and HFD-fed
mice (Fig. 5F). These data suggest that monitoring MIP-TF
gene expression (by BLI) provides a surrogate marker of
pancreatic b-cell function and area.
DISCUSSION
We have generated transgenic mice in which pancreatic
b-cells express a fusion protein of three different imaging
reporters. Expression of the trifusion reporter transgene
had no apparent effect on mouse weight, islet morphology,
fasting blood glucose, or glucose tolerance. We demon-
strated that MIP-TF mouse b-cells were readily identiﬁed
in pancreatic tissue sections using ﬂuorescence micros-
copy, as in previous studies of MIP-EGFP mice (17). Ad-
ditionally, we showed that both BLI and microPET can
noninvasively monitor MIP-TF mouse b-cells. Previous
studies have generated transgenic mice expressing lucif-
erase in their b-cells (3–5). The b-cells of MIP-TF mice
have especially high levels of luciferase activity, perhaps
because the trifusion cDNA expression is enhanced by the
long stretches of the insulin II gene genomic DNA that
surround it and/or because its luciferase has been modiﬁed
for greater enzymatic activity at 37°C.
Using microPET/CT, we could clearly delineate pref-
erential accumulation of [
18F]FHBG in the pancreas of
MIP-TF mice. Noninvasive microPET imaging of mouse
pancreatic b-cells is technically challenging because of the
small size of mice relative to small animal PET scanner
spatial resolution, the small size of their pancreas, and
its proximity to tracer excretion pathways (9–11,14). Six
hours postprobe injection, the vast majority of the probe
had cleared through its excretion pathway, and there was
sufﬁcient probe retention in the pancreas such that the
pancreas could be readily discerned from surrounding
organs. After rendering mice diabetic by STZ administra-
tion, probe retention in the pancreas region was reduced
by 91–95% in individual mice, conﬁrming that the probe
was originally retained by b-cells. The magnitude of pan-
creatic microPET signals showed a signiﬁcant correlation
with pancreatic bioluminescence from individual mice.
Correlation between reporter proteins originating from the
same fusion cDNA has been observed in previous in vitro
and in vivo studies of tumors expressing linked reporter
molecules (e.g., 15,16,26) and allows ﬂexibility in the mo-
dalities used to monitor biological processes.
After administering a high dose of STZ, bioluminescent
signals from the MIP-TF mice dropped to essentially back-
ground levels, proving to be further evidence that the ex-
pression of luciferase was b-cell speciﬁc. Using the more
slowly progressing multiple low-dose STZ model of type 1
diabetes, we observed a progressive loss of pancreatic
bioluminescent signals, which preceded the appearance of
hyperglycemia. By the time the mice developed severe
hyperglycemia, only 8% of the bioluminescent signal re-
mained. The timing and magnitude of the changes in pan-
creatic bioluminescence correspond well with the gradual
loss of b-cells previously described in C57BL/6 mice after
administration with low-dose STZ (27,31). There was a lin-
ear correlation between b-cell area and bioluminescence
for individual MIP-TF mice, suggesting that noninvasive
monitoring of MIP-TF gene expression by BLI can provide
a biomarker of endogenous b-cell mass. In addition, we
show that treatment with GCV induces hyperglycemia
concomitant with a large decrease in bioluminescence
J. YONG AND ASSOCIATES
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highly toxic to multiple organ systems, MIP-TF mice
together with GCV treatment may provide a less toxic
alternative to induce experimental type 1 diabetes. Po-
tentially, this also provides a suicide gene system to
speciﬁcally ablate b- c e l l sa r i s i n gf r o ms t e mc e l lt h e r a p y
using MIP-TF stem cells.
Hyperglycemia has been reported to induce proinsu-
lin expression in the mouse liver and other organs (24).
Tg(RIP-luc) mice that were rendered diabetic by STZ
FIG. 5. CCD imaging of MIP-TF mice in the HFD model of type 2 diabetes. A: Longitudinal monitoring of pancreas region bioluminescence (BL)
from MIP-TF mice fed a normal (white bar) or a HFD (black bar). Data shown are the mean maximum photons/seconds/squared centimeters/
steradian 6 SEM. Solid line indicates mean body weight 6 SEM for MIP-TF mice fed a HFD; dashed line is that for control mice on a normal diet
(n = 4 to 5 mice/group). B: Longitudinal monitoring of IPGTT in MIP-TF mice fed a HFD (solid line) or normal diet (dashed line). *P < 0.05 for HFD
vs. normal diet at indicated time point by t test. ** P < 0.05 for HFD at indicated time point vs. the baseline at day 0 by t test. Bonferroni ad-
justment was applied for post hoc t test following repeated-measures ANOVA. C: Inverse correlation between MIP-TF mouse weight and the light
detected from a luminescent bead placed on the pancreas. A luminescent bead that provides a constant light source was used to assess the extent
to which obesity attenuated luminescence. Bead luminescence was inversely correlated with body weight (R
2 = 0.66 with P < 0.01). Individual mice
are represented by black circles. D: After correction for reduced tissue transparency, bioluminescence from the pancreas region of HFD-fed mice
(black bar) was an average of 3.6-fold higher than control mice (white bar) at day 60. Data shown are average 6 SEM (n = 4 to 5 mice/group). P <
0.05 by two-tailed t test. E: AUC-IPGTT (obtained at day 60) was linearly correlated with bioluminescence after correction (P < 0.01). Individual
mice are represented by black dots (n =8 ) .F: Data shown are pancreatic b-cell area vs. corrected bioluminescence for individual control and HFD-
fed MIP-TF mice (n = 4 mice/group; P < 0.05).
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but the expression of proinsulin/insulin was not dem-
onstrated at the protein level in their liver (23). Although
our MIP-TF mice express approximately 20-fold higher
levels of pancreatic luciferase activity compared with
Tg(RIP-luc) mice, we never detected bioluminescent signals
from diabetic MIP-TF mouse livers or from other organs,
indicating that if hyperglycemia activates transgene ex-
pression in liver cells or in other organs, it occurs in rare
cells, or at extremely low levels, in these mice.
We generated the MIP-TF mice in C57BL/6 background
because this mouse strain provides a very useful model of
early type 2 diabetes when placed on a HFD (28,32–34).
MIP-TF mice displayed a rapid weight gain shortly after
being placed on a HFD, as well as progressively impaired
glucose tolerance and elevated fasting blood glucose lev-
els, as expected. A prominent feature of this model is in-
creased mesenteric adipose tissue (35), and this overlaying
tissue can attenuate pancreatic bioluminescence. Using
a constant ﬂuorescent standard to quantify this attenuation
(as described in [5,18]), we corrected the pancreatic bio-
luminescence based on the animal’s weight and found that
the pancreatic signals in MIP-TF mice were about 3.6-fold
greater than that from MIP-TF mice on a normal diet. The
corrected bioluminescence showed a signiﬁcant correla-
tion with pancreatic b-cell area for individual MIP-TF
mice, again suggesting that noninvasive monitoring of
MIP-TF gene expression by BLI can provide a biomarker
of endogenous b-cell mass. The increased b-cell area in
HFD-fed mice reﬂects, in large part, increased insulin re-
sistance. Consistent with this, we observed that the cor-
rected pancreatic bioluminescence signals from individual
mice correlated with their AUC-IPGTT. Although CCD im-
aging in type 2 diabetes models may have to take into
account changes in the animal’s body weight, microPET
detection of reporter gene expression is unaffected by tis-
sue depth since high-energy g-photons are much more tis-
sue penetrating (8), and can be corrected for attenuation if
needed, but microPET imaging is much more expensive.
In summary, we have generated transgenic MIP-TF
C57BL/6 mice in which the b-cells express a fusion of
three different imaging reporters. We have demonstrated
imaging of MIP-TF pancreatic b-cells by ﬂuorescent mi-
croscopy, BLI, and microPET. The MIP-TF mice enabled
noninvasive monitoring of b-cells in models of type 1 di-
abetes and type 2 diabetes. We believe the MIP-TF mice
can expedite studies in a broad range of diabetes re-
search, including studies of b-cell development, diabetes
pathogenesis, stem cell differentiation into b-cells, trans-
differentiation, and islet survival after transplantation.
We are currently breeding the TF gene into the NOD
mouse background and hope to provide a new tool for
studying b-cell loss and b-cell replication in the context of
autoimmunity.
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